Walleye Capital LLC Invests $75,000 in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Walleye Capital LLC bought a new position in Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating) during the second quarter, HoldingsChannel.com reports. The fund bought 15,355 shares of the company’s stock, valued at approximately $75,000.

Other large investors have also recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of Organogenesis in the 2nd quarter worth about $27,000. Ameritas Investment Partners Inc. increased its holdings in shares of Organogenesis by 80.1% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after buying an additional 2,396 shares during the last quarter. TrinityPoint Wealth LLC bought a new stake in shares of Organogenesis in the 2nd quarter worth about $63,000. Lazard Asset Management LLC increased its holdings in shares of Organogenesis by 3,808.2% in the 1st quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock worth $69,000 after buying an additional 8,873 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in shares of Organogenesis in the 2nd quarter worth about $77,000. 44.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Oppenheimer downgraded shares of Organogenesis from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 10th. BTIG Research downgraded shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Thursday, November 10th.

Organogenesis Stock Performance

Shares of NASDAQ:ORGO opened at $2.59 on Monday. The company has a market capitalization of $339.07 million, a price-to-earnings ratio of 5.63 and a beta of 1.73. Organogenesis Holdings Inc. has a 12 month low of $2.23 and a 12 month high of $10.66. The firm’s 50-day moving average is $3.20 and its 200 day moving average is $4.45. The company has a current ratio of 2.58, a quick ratio of 2.31 and a debt-to-equity ratio of 0.26.

Organogenesis Company Profile

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Read More

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating).

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.